**Risk Reducing Surgery – Mastectomy or Oophorectomy**

|  |  |
| --- | --- |
| **Commissioning decision** | The CCG will provide funding for risk reducing surgery for patients with a mutation, high risk patients or high risk families confirmed by our Genetics Service in Bristol who meet the criteria. The policy does not cover women who have a personal history of breast cancer. |

**Policy Statement:**

|  |
| --- |
| Risk reducing mastectomy or oophorectomy is commissioned if **ONE** of the following indications applies:   * Women who have a mutation such as BRCA1, BRCA2 or TP53 (other genes may be relevant such as Lynch, RAD51C/D) confirmed by our Genetics Service in Bristol * Women from high risk families with a family history confirmed where no mutation has been identified, and a first degree relative with a breast/ovarian cancer * Women identified as high risk by the Clinical Genetics Service without a gene mutation * Women who have had lymphoma and have undergone mantle radiotherapy (these patients will not have been reviewed by Clinical Genetics) * Women at high risk of ovarian cancer   **AND ALL OF THE BELOW**   * Undergone genetic and psychological counselling with risk assessed by the Clinical Genetics Service (with the exception of lymphoma patients who have had mantle radiotherapy and undergone psychological counselling)   **AND**   * Chemoprevention has been discussed for post-menopausal women at high risk of developing breast or ovarian cancer   **AND**   * Modifiable risk factors have been discussed and patients have been signposted to Healthy Lifestyles Gloucestershire if appropriate   **Risk-reducing surgery will not usually be commissioned for:**   * People who have a limited life expectancy from their cancer or conditions |

**Rationale:**

|  |
| --- |
| Risk reducing surgery will be offered to patients who have a high risk of developing breast or ovarian cancer. As patients are prepared to accept different levels of risk they should have been referred and assessment made by the Clinical Genetics Team, including genetic counselling to enable communication of risk. Due to the psychological impact of this diagnosis psychological counselling may also be appropriate. |

**Plain English Summary:**

|  |
| --- |
| **What is risk reducing surgery?**  Risk reducing surgery is an operation that removes healthy body tissue in order to significantly reduce the risk of cancer developing. It can be used to reduce the risk of developing both breast and ovarian cancer. Risk reducing breast surgery removes the breast tissue (called a mastectomy) and risk reducing ovarian surgery removes the ovaries and fallopian tubes (called an oophorectomy).  **What does this policy mean for me?**  Risk reducing surgery is only appropriate for a small number of women with a high risk of developing breast or ovarian cancer in their lifetime. The policy sets out the criteria that a patient should meet in order for risk reducing surgery to be funded by the NHS in Gloucestershire. |

**Evidence base:**

|  |
| --- |
| **Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer** – <https://www.nice.org.uk/guidance/cg164>, The National Institute for Health and Care Excellence  **Prophylactic surgery in hereditary breast/ovarian cancer syndrome** - <http://www.ncbi.nlm.nih.gov/pubmed/12886864>, The National Center for Biotechnology Information |

**Link to application form – Not applicable**

**For further information please contact** [**glccg.ifr@nhs.net**](mailto:glccg.ifr@nhs.net)

|  |  |
| --- | --- |
| **Date of application** | 1 August 2018 |
| **Policy review date** | March 2024 |

**Consultation**

|  |  |
| --- | --- |
| **Consultee** | **Date** |
| GHNHSFT | December |
| GP Membership (via What’s New This Week | July/August 2018 |
|  |  |
| Has the consultation included patient representatives? | Yes (via ECCP membership |

**Policy sign off**

|  |  |
| --- | --- |
| **Reviewing Body** | **Date of review** |
| Effective Clinical Commissioning Policy Group | 01/02/2018 |
| Integrated Governance and Quality Committee | 31/06/2018 |

**Version Control**

|  |  |  |  |
| --- | --- | --- | --- |
| **Version Number** | **Type of Change** | **Date** | **Description of Change** |
| 2 | Plain English Summary & review date | 11.6.20 | Plain English summary wording updated. Review date changed to December 2020 |
| 3 | Slight wording amendment  Review date | 10.12.20 | Wording to include ‘All of the below’ also AND inserted between second set of criteria.  Review date changed to March 2024 |